Cansinobio announced on December 4, 2024, that one of the actual controllers, Mao Huihua, adjusted her H shares holding method. Mao Huihua will transfer the 1,127,372 shares of H shares and 11,387 shares of H shares held by SCHELD Holding Limited, which she controls, to be held separately by Medicharms LLC and herself. This adjustment does not affect the total number and proportion of shares controlled by the actual controllers of the company, nor does it involve market shareholding or changes in company control. Mao Huihua's adjustment this time is for asset planning purposes. Medicharms was established in Delaware, USA on August 28, 2024, with Mao Huihua as its sole shareholder. After the adjustment, Mao Huihua directly holds 4,409,500 shares of A shares and 4,797,328 shares of...Show More

Cansinobio announced on December 4, 2024, that one of the actual controllers, Mao Huihua, adjusted her H shares holding method. Mao Huihua will transfer the 1,127,372 shares of H shares and 11,387 shares of H shares held by SCHELD Holding Limited, which she controls, to be held separately by Medicharms LLC and herself. This adjustment does not affect the total number and proportion of shares controlled by the actual controllers of the company, nor does it involve market shareholding or changes in company control. Mao Huihua's adjustment this time is for asset planning purposes. Medicharms was established in Delaware, USA on August 28, 2024, with Mao Huihua as its sole shareholder. After the adjustment, Mao Huihua directly holds 4,409,500 shares of A shares and 4,797,328 shares of H shares in the company, and indirectly holds 6,000,000 shares of H shares and 1,127,372 shares of H shares through CHAMPDEN and Medicharms, totaling 6.6010% of the company's shares. Mao Huihua's spouse, Chao Shoubai, has not changed his shareholding. After this adjustment in shareholding method, Mao Huihua, along with the company's controlling shareholders Yu Xuefeng, Zhu Tao, and Qiu Dongxu, signed a supplementary agreement to the "Joint Action Agreement" on December 3, 2024, where Medicharms will inherit all obligations from SCHELD in the agreement. The four actual controllers collectively control 31.2944% of the company's shares, with no changes occurring.